-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on GRI Bio, Raises Price Target to $35

Benzinga·09/22/2025 09:50:10
Listen to the news
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and raises the price target from $34 to $35.